Firm to make catheters for heart diseases

Image
IANS Bangalore
Last Updated : May 31 2013 | 9:48 PM IST

Eurocor GmbH, a group firm of medical technology leader Opto Circuits India Ltd, Friday entered into a licensing agreement with Biosensors International Group Ltd, a Singapore-based medical devices maker, to manufacture catheters for treating heart diseases.

As part of the agreement, Eurocor will manufacture three medical devices using Biosensors' drug eluting balloon (DEB) technology for treating coronary and artery diseases, while the latter will market them worldwide.

"The three devices are drug-eluting balloon dilatation catheters designed for percutaneous transluminal angioplasty. The first one -- BioStream has been developed for coronary arteries, BioPath for treating patients with peripheral arterial disease and BioPath 035 for peripheral intervention above knee," the company said in a statement here.

The devices will feature Eurocor's proprietary coating, delivering paclitaxel, an anti-restenotic drug, used in DEB applications.

"The innovative devices will complement our cardiac stents and facilitate our entry into the peripheral vascular disease market," Biosensors cardiovascular division president Jeffrey B. Jump said in the statement.

The devices will be launched in European markets and in select regions across Asia, Africa and West Asia after securing the European Conformance Marking (CE) in next six weeks.

"The agreement validates our DEB products and enables us to enter the rapidly-growing sector of the interventional devices market," Eurocor chief operating officer Antonino Laudani said.

As a vertically integrated medical technology group, the Bangalore-based Opto Circuits specialises in primary, acute and critical care devices for global markets.

Specialising in research, development and manufacture of cardiovascular and endovascular products, Eurocor provides interventional physicians with coronary stents and special cardiovascular and endovascular devices.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 31 2013 | 9:34 PM IST

Next Story